Main Menu
About
Overview
Amgen History
Mission and Values
Leadership
Amgen Foundation
Awards and Accolades
How We Operate
Overview
Corporate Governance
Business Ethics and Compliance
Policies, Practices and Disclosures
Science
Overview
Research and Development Strategy
Overview
Human Data
AI & Data Science
Multispecifics & Other Modalities
Clinical Trial Innovation
Pipeline
Amgen Science Podcasts
Scientific Advisory Boards
Biosimilars
Clinical Trials
Overview
About Clinical Trials
Amgen Clinical Trials
Clinical Trial Diversity and Representation
Information for Healthcare Professionals
Clinical Trial Transparency, Data Sharing and Disclosure Practices
Clinical Out-of-Hours Support program
Investigator Sponsored Studies
Scientific Community Initiatives
Overview
Educational Outreach Program
Postdoctoral Fellows Program
Scientific Conferences Program
Start-Up Network Program
Manufacturing
Overview
Innovation
Quality
Reliability
PRODUCTS
Overview
Medical Information
Counterfeit Drug Statement
Safety Data Sheets
Global Patient Safety
Overview
Who We Are
Our Commitment
What We Do
Adverse Event and Product Complaint Reporting
Responsibility
Overview
Environmental, Social & Governance Report 2022
Environment, Social and Governance Strategy
Healthy People
Overview
Access to Healthcare
Health Equity
Healthy Society
Overview
Diversity, Inclusion and Belonging
Human Capital Management
Community Investment and Amgen Foundation
Supplier Diversity
Healthy Planet
Overview
Environmental Sustainability
Supplier Sustainability
A Healthy Amgen
Overview
Corporate Governance
Business Ethics and Compliance
Ethical Research
Patient Safety
Product Quality
Cybersecurity and Data Privacy
Reporting and Metrics
Overview
Summary of Data
CDP
Archived Reports
Stories
All Stories
Responsibility
People and Culture
Science and Innovation
Patients
Leadership
Popular Tags
COVID-19
Supporting Our Staff
Leveraging Our Science
Serving Our Communities
Newsroom
Partners
Investors
Careers
Amgen Worldwide
All Stories
Responsibility
People and Culture
Science and Innovation
Patients
Leadership
Popular Tags
COVID-19
Supporting Our Staff
Leveraging Our Science
Serving Our Communities
About
Overview
Amgen History
Mission and Values
Leadership
Amgen Foundation
Awards and Accolades
How We Operate
Corporate Governance
Business Ethics and Compliance
Policies, Practices and Disclosures
Science
Overview
Research and Development Strategy
Human Data
AI & Data Science
Multispecifics & Other Modalities
Clinical Trial Innovation
Pipeline
Amgen Science Podcasts
Scientific Advisory Boards
Biosimilars
Clinical Trials
About Clinical Trials
Amgen Clinical Trials
Clinical Trial Diversity and Representation
Information for Healthcare Professionals
Clinical Trial Transparency, Data Sharing and Disclosure Practices
Clinical Out-of-Hours Support Program
Investigator Sponsored Studies
Scientific Community Initiatives
Educational Outreach Program
Postdoctoral Fellows Program
Scientific Conferences Program
Start-Up Network Program
Manufacturing
Innovation
Quality
Reliability
PRODUCTS
Overview
Medical Information
Counterfeit Drug Statement
Safety Data Sheets
Global Patient Safety
Who We Are
Our Commitment
What We Do
Adverse Event and Product Complaint Reporting
Responsibility
Overview
Environmental, Social & Governance Report 2022
Environment, Social and Governance Strategy
Healthy People
Access to Healthcare
Health Equity
Healthy Society
Amgen Foundation and Community Investment
Diversity, Inclusion and Belonging
Human Capital Management
Supplier Diversity
Healthy Planet
Environmental Sustainability
Supplier Sustainability
A Healthy Amgen
Corporate Governance
Business Ethics and Compliance
Ethical Research
Patient Safety
Product Quality
Cybersecurity and Data Privacy
Reporting and Metrics
Summary of Data
CDP
Archived Reports
Stories
All Stories
Responsibility
People and Culture
Science and Innovation
Patients
Leadership
Popular Tags
COVID-19
Supporting Our Staff
Leveraging Our Science
Serving Our Communities
Newsroom
Partners
Investors
Careers
X
Home
>
Stories
>
KRASG12C Inhibition Explained, Greg Friberg, Vice President and Therapeutic Area Head for Global Development Oncology
>
SCIENCE & INNOVATION
01.25.2021
KRAS
G12C
Inhibition Explained: Featuring Dr. Gregory Friberg, Head of Global Development, Oncology, Greg Friberg, Vice President and Therapeutic Area Head for Global Development Oncology
Share This Story
